Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin Induction and Monotherapy in Kidney Transplant
NCT00076570Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jan 2004
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus in kidney transplant rejection (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Rate of Allograft Rejection at 3 years. Started Jan 2004; status: completed.
02
Drugs
sirolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00076570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076570.